Latent Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 35)
Latent Health logo

Latent Health

EmergingDigital Health

Medication Access & Prior Authorization AI

Raised $80M Series A (Mar 2026) co-led by Spark Capital and Transformation Capital. 2M+ patients/year. Partners with 50% of top 20 US health systems. McKesson Ventures strategic investor.

AI VisibilityBeta
Overall Score
D35
Category Rank
#545 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
31
Gemini
40

About

Latent Health is a medication access and prior authorization automation platform that uses its Clinical Reasoning Engine to ingest EHR data, interpret drug approval criteria, and automate the full medication access workflow end-to-end. The company raised $80 million in Series A financing in March 2026 co-led by Spark Capital and Transformation Capital, with McKesson Ventures, General Catalyst, and Y Combinator as co-investors. The platform serves 2 million+ patients annually and is partnered with 50% of the top 20 US health systems.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

35
Overall Score
90
#545
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
34
ChatGPT
92
31
Perplexity
93
40
Gemini
89
33
Claude
96
35
Grok
95

Key Details

Category
Medication Access & Prior Authorization AI
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Latent Health
Medication Access & Prior Authorization AI

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.